JUNS Jupiter Neurosciences Inc Forecast, Technical & Fundamental Analysis
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform... Show more
JUNS is expected to report earnings to fall 16.67% to -5 cents per share on September 02
Q2'26
Est.
$-0.05
Q1'26
Missed
by $0.01
Q4'25
Est.
$-0.07
Q3'25
Est.
$-0.08
Q2'25
Est.
$-0.07
The last earnings report on May 14 showed earnings per share of -5 cents, missing the estimate of -5 cents. With 3.26M shares outstanding, the current market capitalization sits at 11.09M.
A.I.dvisor tells us that JUNS and KZIA have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that JUNS and KZIA's prices will move in lockstep.
JUNS's RSI Indicator ascends from oversold territory
The RSI Indicator for JUNS moved out of oversold territory on May 21, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 11 similar instances when the indicator left oversold territory. In of the 11 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 21 cases where JUNS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for JUNS just turned positive on June 02, 2026. Looking at past instances where JUNS's MACD turned positive, the stock continued to rise in of 12 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where JUNS advanced for three days, in of 69 cases, the price rose further within the following month. The odds of a continued upward trend are .
JUNS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on June 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on JUNS as a result. In of 23 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JUNS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for JUNS entered a downward trend on May 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: JUNS's P/B Ratio (227.273) is slightly higher than the industry average of (20.966). P/E Ratio (0.000) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). JUNS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (200.000) is also within normal values, averaging (367.026).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. JUNS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JUNS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
